近期国内多地流感季用药需求激增，今日（11.27），中药板块探底回升，中药ETF（560080）一度飘红，盘中成交额已超4600万元！截至11月26日，中药 ETF（560080）最新规模25.9亿元，同类断层领先！ 消息面上，当前全国进入流感流行季，中国疾病防控中心研究员表示，监测数据显示，往年开始进入流感流行季的时间一般都是在10—11月，流行高峰的时 间一般出现在12月中下旬和1月初。抗感冒药物市场需求迅速升温，美团买药数据显示，11月以来平台相关药品订单量环比增长超一倍，中成药因整体调 节、副作用温和等特点成为家庭首选。 中药ETF（560080）标的指数成分股涨跌互现：粤万年青涨超10%，太龙药业涨超2%众生药业涨超1%；下跌方面，以岭药业、白云山、片仔癀、华润三九 微跌。市场观点认为，粤万年青的大涨可能受公司治理结构优化、核心产品参芪降糖片销量增长并成功进入全国集采、流感疫情高发带动抗病毒药物需求激 增催化。 | 序号 | 代码 | 名称 | 估算权重 | 涨跌幅 | 成交额 ▼ | | --- | --- | --- | --- | --- | --- | | 1 | 002317 | 众生药业 ...

Core Viewpoint - Beijing Yiling Pharmaceutical Co., Ltd. is leading the innovation in traditional Chinese medicine through the development of the "Luo Disease Theory" and the integration of AI technology in its production processes [4][10][17]. Group 1: Company Overview - Beijing Yiling Pharmaceutical was established in October 2006 and is a wholly-owned subsidiary of Shijiazhuang Yiling Pharmaceutical Co., Ltd., focusing on research innovation, market expansion, and international cooperation [3]. - The company has developed a comprehensive product system guided by the "Luo Disease Theory," which provides new diagnostic and treatment approaches for complex diseases [4][6]. Group 2: Product Development and Innovation - The company has created a series of clinically effective formulas based on the Luo Disease Theory, targeting major diseases such as cardiovascular diseases, diabetes, and respiratory diseases [6]. - Over 30 years, Yiling has developed an integrated model of traditional Chinese medicine innovation, successfully launching over ten patented traditional Chinese medicines, with five included in the national essential drug list and eleven in the medical insurance directory [6][9]. Group 3: Research and Clinical Trials - Yiling has introduced evidence-based medicine research methods into traditional Chinese medicine, conducting over 40 clinical studies to validate the efficacy of its products [9]. - The company is currently preparing for clinical trials of its Lianhua Yusheng Granules, with the trial expected to start in August 2025 [20]. Group 4: Technological Integration and Production Capacity - Yiling has completed the intelligent transformation of its production line for Lianhua Qingwen Granules, increasing its production capacity from 360 million bags to 1.08 billion bags [13][16]. - The company emphasizes the integration of smart manufacturing technologies to enhance production efficiency and quality control [13][16]. Group 5: Industry Impact and Future Plans - Beijing Daxing Biopharmaceutical Industry Base has become a key area for pharmaceutical health development, with Yiling positioned as an important innovation engine within this ecosystem [17]. - The company aims to deepen its collaboration in research and development, responding to the development plans of the Daxing Biopharmaceutical Industry Base, and continuously enhance its core competitiveness [20].